ClinicalTrials.govpublic full text
Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma
leukemia, b-cell, lymphoma, b-cell, car-t, cd19, cd22, interventional, phase1, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 1046891
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.